A carregar...
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer
Lung cancer has recently been discovered to be an immunological targetable disease, on the basis of the exciting results of the randomized trials with immune checkpoint inhibitors. Nevertheless, the survival benefit appears to not be entirely captured by the usual outcome measures, thus requiring a...
Na minha lista:
| Publicado no: | Transl Lung Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AME Publishing Company
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4700216/ https://ncbi.nlm.nih.gov/pubmed/26798579 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2015.10.08 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|